Drug Trial Radar · NCT01813162
In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products
Last checked: Nov 19, 2026Latest source record: May 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Dec 2013
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- CONRADAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is determine if the local release characteristics and systemic exposure to tenofovir (TFV) 1% gel and a given commonly used vaginal product are impacted by concomitant use
Conditions
- HIV Prevention
Interventions
Tenofovir 1% gelDrug
Vaginal productDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- TFV concentrations in plasma and genital tissue and TFV-DP concentrations in genital tissueTime frame: Assessments will be after product use (see description)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Dept of OBGYN and Reproductive Sciences, UCSF
San Francisco, California
Bronx-Lebanon Hospital Center
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.